Latest News

Bravo to our colleagues in the WHO HIV Department! Pangaea strongly supports WHO's "Treat All" Recommendation that anyone infected with HIV should begin ARV treatment as soon after diagnosis as possible. Now, the hard work begins making this a reality - and Pangaea will be at the forefront of efforts to promote the development of more effective and affordable treatments for all - including those in middle income countries.

Ben Plumley, CEO Pangaea Global AIDS

New policies could help avert more than 21 million deaths and 28 million new infections by 2030

News release - World Health Organization

30 SEPTEMBER 2015 ¦ GENEVA - Anyone infected with HIV should begin antiretroviral treatment as soon after diagnosis as possible, WHO announced Wednesday. With its "treat-all" recommendation, WHO removes all limitations on eligibility for antiretroviral therapy (ART) among people living with HIV; all populations and age groups are now eligible for treatment. The expanded use of antiretroviral treatment is supported by recent findings from clinical trials confirming that early use of ART keeps people living with HIV alive, healthier and reduces the risk of transmitting the virus to partners.

WHO now also recommends that people at "substantial" risk of HIV should be offered preventive antiretroviral treatment. This new recommendation builds on 2014 WHO guidance to offer a combination of antiretroviral drugs to prevent HIV acquisition, pre-exposure prophylaxis (PrEP), for men who have sex with men. Following further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened this recommendation to support the offer of PrEP to other population groups at significant HIV risk. PrEP should be seen as an additional prevention choice based on a comprehensive package of services, including HIV testing, counselling and support, and access to condoms and safe injection equipment. New recommendations on early use of ART and expanded offer of PrEP are contained in WHO’s "Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.” The new guideline stresses that, in order to effectively implement the recommendations, countries will need to ensure that testing and treatment for HIV infection are readily available and that those undergoing treatment are supported to adhere to recommended regimens and are retained in care.

The recommendations were developed as part of a comprehensive update of the "WHO consolidated guidelines on the use of antiretroviral drugs for preventing and treating HIV infection". This early release guideline is shared ahead of the full publication, slated for release later this year, because of their potential for public health impact.

Based on the new recommendations, the number of people eligible for antiretroviral treatment increases from 28 million to all 37 million people who currently live with HIV globally. Expanding access to treatment is at the heart of a new set of targets for 2020 with the aim to end the AIDS epidemic by 2030. These targets include 90% of people living with HIV being aware of their HIV infection, 90% of those receiving antiretroviral treatment, and 90% of people on ART having no detectable virus in their blood.

According to UNAIDS estimates, expanding ART to all people living with HIV and expanding prevention choices can help avert 21 million AIDS-related deaths and 28 million new infections by 2030.

For media inquiries, please contact:

Christian Lindmeier Communications Officer, WHO Telephone: +41 22 791 1948 Mobile: +41 79 5006552 E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Project Inform has published a new informative treatment guide for patients who have been recently been diagnosed with Hepatitis C. As the options for treating hepatitis C (HCV) are increasing, so is the confusion. This is a good problem to have: with more treatment options come more opportunities for people with various HCV genotypes (GT), treatment history and varying levels of cirrhosis to get cured. For more information visit:

Three hundred supporters joined Pangaea for our inaugural Global Health Leadership Dinner on May 12th in Oakland, California. As well as reinforcing the importance of keeping public attention focused on the global response to AIDS, supporters learned more about the important work we do to support countries around the world in their fight against HIV.

Photographs from the evening are available at

The theme of the evening was Africa’s dynamism and creativity, which was reflected in the entertainment provided by Berkeley-based Zimbabwean song and dance troupe, Chinyakare, and venue décor provided by Arts Africans.

We honored four extraordinary local and global heroes who have made a significant difference, saving lives and preventing new HIV infections around the world:

  • Dr Peter Piot, Director, London School of Hygiene and Tropical Medicine, and Founding Executive Director of UNAIDS
  • Dr Huma Abbasi, General Manager of Global Health and Medical, Global Health Champion, Chevron
  • Dr Tsi Tsi Appollo, Deputy Director, HIV and TB Program, Ministry of Health and Child Welfare, Zimbabwe
  • Miss Gloria Lockett, Executive Director, California Prostitutes Education Project (CALPEP)

In addition, Pangaea’s CEO, Ben Plumley announced two new major initiatives:

  • Helping vulnerable LGBTI communities, in countries with strong anti-gay laws and practices, access HIV related services through networks of supportive healthcare professionals. Pangaea will collaborate with the Global Forum on MSM and HIV/AIDS,, on this initiative.
  • Identifying research and program delivery gaps in Pre Exposure Prophylaxis (PREP) for girls and women in the Global South.

For more information about how you can support Pangaea’s mission, please visit You may wish to become a regular contributor, or make a single contribution that is meaningful to you; every cent matters and without your help, we could not support innovative, effective AIDS responses in Africa, Asia, and here at home in Oakland.

In the meantime, Pangaea proudly thanks our honorees, sponsors and supporters for making the evening such a memorable event, with a shared commitment made by all to speak out and loudly about the need for a continued strong global response to AIDS!

This World AIDS Day is a promising one with several new HIV prevention interventions for young women on the horizon.

It is in Zimbabwe's best interest to prepare for these emerging strategies now. Just last year, HIV prevalence among pregnant women aged 15-24 in Zimbabwe was a startling 10.4 percent. This number is indicative of a larger trend in southern Africa where adolescent women are up to eight times more likely to become infected with HIV than young men.

Young women's high rates of HIV are due in part to biological, social and economic factors making them more susceptible. Because efforts to promote abstinence, monogamy and the use of male condoms have not been enough to stop HIV among girls and young women, researchers have been working to develop women-initiated biomedical prevention interventions. Years of scientific exploration here in Zimbabwe and around the world are finally starting to pay off. PrEP (pre-exposure prophylaxis), microbicide gels and rings are three methods that could potentially turn around the endemic rates of HIV in young women.

AIDS is not one uniform global epidemic, but a series of individual epidemics driven by local circumstances. The need for effective HIV treatment programs that reflect particular contexts has never been greater.

A major new program of Pangaea is, to develop and cost a series of single descriptive case studies documenting effective approaches to HIV service delivery in East and Southern Africa. The goal of this project is to document ARV treatment and support programs that are improving the uptake and retention of clients in care. Pangaea is collaborating with the Clinton Health Access Initiative (CHAI), who will be performing the cost estimates for each of the case studies. The selection of programs for the case study development will seek to present information about a diverse set of programs, looking at both community- and facility-based services and at programs addressing urban and rural populations, key affected populations, and programs that are well integrated with other areas of health services including primary care, sexual, reproductive, and maternal health, and TB services. We are particularly interested in identifying effective HIV treatment initiatives that combine the clinical expertise found in the health facilities and the leadership of the local communities to help as many HIV positive people stay in care and on treatment.

The ultimate goal of the project is to produce clear, policy-relevant cost and effectiveness data around best practices in the HIV space. In addition, dissemination of the methodology used to create the case studies and cost estimates can serve as a template for replication of the process at country levels in order to better understand what program models are working. Through this process, Pangaea seeks to improve uptake and scale of HIV services and fill the gaps in the HIV treatment cascade.

The project is funded by the Bill and Melinda Gates Foundation.

As each case study is finalized, it will be posted on this website. Completed case studies include:

37 million People worldwide are living with HIV (amfAR Statistics 2014: Worldwide)

16 million Women living with HIV (United Nations Statistics 2014)

15 million People living with HIV having access to antiretroviral therapy (amfAR Statistics 2014: Worldwide)

5,600 People Contract HIV every day - more than 230 every hour (amfAR Statistics 2014: Worldwide)